Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025: III. Second workshop

Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages)

Table of Contents

Executive summary
I. Introduction
II. Background on the research project
	1. Research questions and objectives of the study
	2. Study approach and research tools
	3. Project past activities
III. Second workshop
	1. Aim and objectives
	2. Participants
	3. Method of work and proceedings
IV. Preliminary findings
	1. The methods: What has been learnt?
		1.1 Methods in context: How did the country teams use the methods?
		1.2 Methods in question: What were the main problems encountered and how to solve them?
		1.3 Relevance of the methods
	2. National drug policies: what has been learnt?
		2.1 Preliminary findings based on NDP indicators
		2.2 Preliminary interpretations based on NDP indicators
		2.3 Preliminary findings based on the political mapping
	3. Cross national analysis: What can be learnt at this stage?
		3.1 Relevance of the methods for cross national comparison
		3.2 Strengths and weaknesses of NDP from a cross national perspective
		3.3 Tentative explanations for cross national variations
	4. Broader capacity building
V. Conclusions of the workshop and follow-up plans
	1. Main outcomes
	2. Next steps
Annex 1: Research proposal
	I. Introduction
	II. The Problem
	III. Research Question and Objectives of Proposed Study
	IV. Study Approach
	V. Anticipated Outcomes
	VI. Methods
	VII. Time Line and Resources
	Selected References
Annex 2: List of participants
Annex 3: Agenda
Annex 4: Questionnaire on NDP performance assessment
Annex 5: Achievements of the national drug policies in the 12 countries
	Bulgaria
	Chad
	Colombia
	Guinea
	India
	Mali
	Philippines
	Sri Lanka
	Thailand
	Viet Nam
	Zambia
	Zimbabwe
Annex 6: Consolidated tables
Other documents in the DAP Research Series

III. Second workshop

The workshop was the second round of group evaluation. It was held in Geneva from 10 to 13 June 1996, and organized and supported financially by the WHO Action Programme on Essential Drugs (DAP/WHO).